Chronic GvHD with pulmonary involvement after filgrastim primed allogeneic BMT.

被引：0
|
作者：
Grosskreutz, CL [1 ]
Rodriguez, A [1 ]
Scigliano, E [1 ]
Ross-Dodds, V [1 ]
Egan, R [1 ]
Fruchtman, SM [1 ]
Isola, LM [1 ]
机构：
[1] Mt Sinai Med Ctr, New York, NY 10029 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5375
引用
收藏
页码：450B / 450B
页数：1
相关论文
共 50 条
  • [31] Detection of MRD and relapse rates in patients with CML in advanced phase after allogeneic PBSCT compared to BMT.
    Elmaagacli, AH
    Beelen, DW
    Metzen, D
    Opalka, B
    Seeber, S
    Schaefer, UW
    [J]. BONE MARROW TRANSPLANTATION, 1999, 23 : S58 - S58
  • [32] Host NKT cells can suppress GVHD after adoptive transfer in allogeneic BMT
    Yang, J.
    [J]. VOX SANGUINIS, 2008, 95 : 27 - 27
  • [33] Cobalt-protoporphyrine protects endothelium against irradiation and prolongs survival after experimental allogeneic BMT.
    Ewing, P
    Andrea, W
    Guenther, E
    Reinhard, A
    Ernst, H
    Armin, G
    [J]. BLOOD, 2001, 98 (11) : 653A - 653A
  • [34] Effective management of chronic graft versus host disease (GVHD) in the allogeneic BMT patient.
    Rutkowski, D
    Paplham, P
    Monaco, K
    [J]. ONCOLOGY NURSING FORUM, 2005, 32 (02) : 490 - 491
  • [35] Early PCR-negativity after allogeneic BMT in adults with t(4;11) ALL in the absence of acute or chronic GVHD
    D'Sa, S
    Verfuerth, S
    Vyas, P
    Langabeer, S
    Perry, A
    Peniket, A
    Mackinnon, S
    [J]. BONE MARROW TRANSPLANTATION, 1999, 23 (07) : 695 - 696
  • [36] Efficacy and toxicity of CD4+ donor T lymphocyte infusion for treatment of relapsed chronic myelogenous leukemia (CML) after allogeneic BMT.
    Alyea, EP
    Canning, C
    Collins, H
    Pickett, C
    Wang, Y
    Soiffer, RJ
    Ritz, J
    [J]. BLOOD, 1996, 88 (10) : 2715 - 2715
  • [37] Early PCR-negativity after allogeneic BMT in adults with t(4;11) ALL in the absence of acute or chronic GVHD
    S D’Sa
    S Verfuerth
    P Vyas
    S Langabeer
    A Perry
    A Peniket
    S Mackinnon
    [J]. Bone Marrow Transplantation, 1999, 23 : 695 - 696
  • [38] Monitoring myeloid and lymphoid chimerism with DNA markers is an useful tool in predicting early relapse after allogeneic BMT.
    Galavotti, R
    Trabetti, E
    Fasolo, R
    de Sabata, D
    Benedetti, F
    Pignatti, PF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A250 - A250
  • [39] Diagnostic yield of bronchoalveolar lavage (BAL) and transbronchial biopsy (TBB) in patients with BO(OP) after allogeneic BMT.
    Blau, IW
    Basara, N
    Grothaus, B
    Rudolphi, M
    Fauser, AA
    Kiehl, MG
    [J]. BLOOD, 1998, 92 (10) : 330B - 330B
  • [40] Risk assessment in patients with Ph+CML at first relapse after allogeneic BMT. An EBMT retrospective analysis
    Guglielmi, C
    Arcese, W
    Hermans, J
    Gratwohl, A
    Kolb, HJ
    Niederwieser, D
    Apperley, J
    [J]. BONE MARROW TRANSPLANTATION, 1999, 23 : S59 - S59
12345